Rachel Manahan, PhD

Neurocrine Biosciences, Inc.
San Diego, California, United States

Disclosure information not submitted.

Presentation(s):

• SAT-465 - Long-Term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone and Improved Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-465 - Long-Term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone and Improved Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-466 - Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11Β-Hydroxylase Deficiency: A Case Series

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-466 - Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11Β-Hydroxylase Deficiency: A Case Series

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SUN-465 - Long-Term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses and Improves Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric

  Sunday, June 14, 2026
  12:00 PM - 1:30 PM CT

• SUN-465 - Long-Term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses and Improves Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• ORF32-05 - Characterization of Children and Adolescents with Classic CAH WHO Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont

  Sunday, June 14, 2026
  2:25 PM - 2:40 PM CT